The proxy is routine with no contested items or shareholder proposals, suggesting a low-probability event for the stock. The key catalyst to watch is the CEO transition to Eric Honroth on November 2, 2026, and any strategic shifts he may signal in subsequent quarters. The strong Q1 FY2027 Med Tech growth (13.2%) and improved adjusted EBITDA ($5.0M vs $2.2M) provide a positive backdrop for the annual meeting vote.
Price Chart
Executive Summary
AngioDynamics filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval for the election of two Class II directors, ratification of Deloitte & Touche as auditor, an advisory say-on-pay vote, and an amendment to the 2020 Equity Incentive Plan to increase the share reserve by 1,000,000 shares. The filing is routine governance, with no contested director elections or shareholder proposals. The concurrent Q1 FY2027 earnings release (filed the same day) showed continued Med Tech growth (13.2%) and improved adjusted EBITDA, providing positive context for the proxy's compensation proposals.
Key Facts
- Annual Meeting scheduled for November 17, 2026, to be held virtually.
- Shareholders to elect two Class II directors: Eileen O. Auen and Jan Stern Reed; incumbent Howard W. Donnelly is retiring.
- Board recommends a FOR vote on all four proposals: director election, auditor ratification, say-on-pay, and equity plan amendment.
- Proposal 4 seeks to increase the 2020 Equity Incentive Plan share reserve from 9,050,000 to 10,050,000 shares (a 1,000,000 share increase).
- Last year's say-on-pay vote received approximately 93.1% approval, indicating strong shareholder support.
- CEO James C. Clemmer is retiring effective November 2, 2026, and will be succeeded by Eric Honroth; Clemmer will serve as a consultant for one year post-retirement.
- CEO total compensation for FY2026 was $6,060,145, with 64% of target compensation performance-based.
- FY2026 GAAP revenue increased 9.5% to $320.2 million, but net loss widened to $36.7 million.
- Concurrent Q1 FY2027 earnings (filed same day) showed net sales of $80.9 million (+6.9% YoY), Med Tech growth of 13.2%, and adjusted EBITDA of $5.0 million.
- No shareholder proposals were included in the proxy statement.
Financial Impact
The proxy statement itself does not contain a direct financial impact. The proposed equity plan amendment would increase potential dilution by approximately 1.7 percentage points (from ~15.5% to ~17.2% fully diluted). The concurrent Q1 FY2027 earnings showed a net loss of $7.1 million on $80.9 million revenue.
Risk Factors
- CEO transition risk: new CEO Eric Honroth has no prior experience at AngioDynamics, and execution of the strategic plan may face a learning curve.
- Continued net losses: GAAP net loss widened to $36.7 million in FY2026, and the company remains unprofitable on a GAAP basis.
- Dilution from equity plan amendment: the 1,000,000 share increase would increase fully diluted dilution from ~15.5% to ~17.2%.
- Gross margin headwinds: the company expects lower gross margin in H2 FY2027 vs H1, and tariff refunds that benefited Q1 FY2027 may not repeat.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001140361-26-039022 |
| Document: 0001140361-26-039022-index-headers.html | 0001140361-26-039022 |
| Document: 0001140361-26-039022-index.html | 0001140361-26-039022 |
| Document: 0001140361-26-039022.txt | 0001140361-26-039022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | DEFA14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | DEF 14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Jul 14, 2026 15w ago | 8-K | $13.00 $13.71 | ▲ +5.46% | ▲ +6.76% | $12.26 (−5.69%) |
Apr 2, 2026 29w ago | 8-K | $10.31 $9.80 | ▼ −4.95% | ▼ −8.57% | $12.26 (+18.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers